This research poster summarizes experiments investigating the effect of glucose deprivation on promoter activity in cancer and non-cancer cell lines. The experiments found no difference in promoter activity between glucose-deprived and non-deprived cells, or between cancer and non-cancer cells. However, further experiments are needed using different glucose concentrations before conclusions can be drawn. The poster outlines the materials, methods, results and future work planned to further study how specific promoters respond to glucose and other stresses.
ASCO 2015 Melanoma Immunotherapy
Thomas Olencki, DO Division of Medical Oncology Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
TWIST1 protein (twist-related protein 1) is a transcriptional regulator encoded by the TWIST1 gene in humans. It is a basic helix-loop-helix transcription factor and is known to play a prominent role in cancer metastasis.
Sipuleucel_T Immunotherapy for Metastatic Prostate Cancer after Failing Hormo...mjavan2001
This PowerPoint presentation demonstrates findings on a clinical trial of sipuleucel-T in HRPC patients to evaluate overall survival in this group. The FDA approval of Provenge was based on the results of IMPACT study.
ASCO 2015 Melanoma Immunotherapy
Thomas Olencki, DO Division of Medical Oncology Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio
TWIST1 protein (twist-related protein 1) is a transcriptional regulator encoded by the TWIST1 gene in humans. It is a basic helix-loop-helix transcription factor and is known to play a prominent role in cancer metastasis.
Sipuleucel_T Immunotherapy for Metastatic Prostate Cancer after Failing Hormo...mjavan2001
This PowerPoint presentation demonstrates findings on a clinical trial of sipuleucel-T in HRPC patients to evaluate overall survival in this group. The FDA approval of Provenge was based on the results of IMPACT study.
RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical dataPaul D. Rennert
Presented at the Immuno-Oncology Summit August 31, 2016. Studies from ASCO16 on immune checkpoint combinations, immune checkpoints with other therapies, immune checkpoints and CAR T, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy.
Antibody Directed Enzyme Prodrug therapy is a technique of active drug targeting therapy which was developed to reduce cancer chemotherapy associated Toxicity
Presentation focusing on what is cancer immunotherapy is, what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints, things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets and measuring immunotoxicity / immunopharmacology. It also looks at what if your chosen therapeutic has no pharmacologically relevant non-clinical safety species.
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...Pranav Sopory
Seminar held on Genetic and epigenetic biomarkers for therapeutic monitoring in neurological disorders.
Multiple Sclerosis, Alzheimer's Disease and Parkinson's Disease.
Biomarkers and epigenetic explained. New epigenetic drug targets.
Therapeutic Club on Tauopathy. Its pathophysiology and therapeutic targets. Interactive session held at All India Institute of Medical Sciences, New Delhi - 110029 on 28th October 2017.
Development of cell culture samples for drug screening with bone marrow stem ...Apollo Hospitals
Side population (SP) refers to a group of cells, which is capable to efflux Hoechst 33342, a DNA-binding dye. SP cells exist both in normal and tumor tissues. SP abundance is used as an indicator for disease prognosis and drug screening in some studies. Our study concentrates on the factors influencing SP analysis.
Immunotherapy: Novel Immunomodulatory TargetsPaul D. Rennert
An approach to discovering new immunotherapy targets for oncology is introduced and examples presented. New programs from biotech and pharma are discussed.
RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical dataPaul D. Rennert
Presented at the Immuno-Oncology Summit August 31, 2016. Studies from ASCO16 on immune checkpoint combinations, immune checkpoints with other therapies, immune checkpoints and CAR T, and other studies that enrich our understanding of immuno-oncology as a broad-based discipline for cancer therapy.
Antibody Directed Enzyme Prodrug therapy is a technique of active drug targeting therapy which was developed to reduce cancer chemotherapy associated Toxicity
Presentation focusing on what is cancer immunotherapy is, what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints, things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets and measuring immunotoxicity / immunopharmacology. It also looks at what if your chosen therapeutic has no pharmacologically relevant non-clinical safety species.
Genetic and epigenetic biomarkers for therapeutic monitoring in neurological ...Pranav Sopory
Seminar held on Genetic and epigenetic biomarkers for therapeutic monitoring in neurological disorders.
Multiple Sclerosis, Alzheimer's Disease and Parkinson's Disease.
Biomarkers and epigenetic explained. New epigenetic drug targets.
Therapeutic Club on Tauopathy. Its pathophysiology and therapeutic targets. Interactive session held at All India Institute of Medical Sciences, New Delhi - 110029 on 28th October 2017.
Development of cell culture samples for drug screening with bone marrow stem ...Apollo Hospitals
Side population (SP) refers to a group of cells, which is capable to efflux Hoechst 33342, a DNA-binding dye. SP cells exist both in normal and tumor tissues. SP abundance is used as an indicator for disease prognosis and drug screening in some studies. Our study concentrates on the factors influencing SP analysis.
Immunotherapy: Novel Immunomodulatory TargetsPaul D. Rennert
An approach to discovering new immunotherapy targets for oncology is introduced and examples presented. New programs from biotech and pharma are discussed.
Dr. Ananda Kumar Kondepati, M.D. and
Dr. Shalini D. Pasumarthi, M.D.
Canada, 2015
Clinical Research Program Supervisor:
Pr. Peivand Pirouzi, Ph.D., M.B.A., C.C.P.E.
Environment inside even a small tumor is characterized by total (anoxia) or partial oxygen deprivation, hypoxia. It has been shown that radiotherapy and some conventional chemotherapies may be less effective in hypoxia, and therefore it is important to investigate how different drugs act in different microenvironments. In this study we perform a large screening of the effects of 19 clinically used or experimental chemotherapeutic drugs on four different cell lines in conditions of normoxia, hypoxia and anoxia.
Effectiveness of Resveratrol on Metastasis: A Reviewiosrphr_editor
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).